Sangtech Lab says CellNet PR is first solvent-free whole blood leukoreduction filter
Sangtech Lab introduced CellNet PR, a whole blood inline leukoreduction filter made without organic solvents or process wastewater, and said the product is the first commercial filter of its kind. The company says the manufacturing process and DEHP-free options could give blood services a lower-footprint supply-chain option without sacrificing filtration performance.
Why it matters: - Sangtech Lab is targeting the environmental footprint of blood filtration manufacturing, not just the performance of the finished filter. - CellNet PR is positioned as a supply-chain sustainability upgrade for blood services that want to reduce solvent use and wastewater before blood is even collected. - The product also adds a materials-safety angle with DEHP-free housing and media, which matters to regulators and transfusion providers.
What happened: - Sangtech Lab announced CellNet PR in Taipei, Taiwan, on November 17, 2026. - The company says CellNet PR is the world’s first and only commercial whole blood inline leukoreduction filter manufactured without organic solvents or process wastewater. - Sangtech says the filter media is processed through a patented supercritical-CO₂ system rather than conventional solvent-based wet chemistry. - The company said CellNet PR is available through filter media and semi-finished filters supplied to medical device manufacturers and research institutions worldwide. - Sangtech says the products are produced from an ISO 13485 facility in Yilan, Taiwan.
The details: - Leukoreduction filters remove white blood cells from donated blood to improve transfusion safety. - Conventional commercial production typically uses hydrophilic agents dissolved in organic solvents such as ethanol, acetone or tert-butanol, followed by washing steps. - Sangtech says its process uses a closed supercritical-CO₂ system in which CO₂ is recovered and reused. - The company says media processing generates zero process water and uses no organic solvents at any stage. - Sangtech cites a measured carbon footprint of 7.68 kg CO₂e per kilogram of filtration media, using a gate-to-gate calculation. - CellNet PR is offered with zero-DEHP housing in both hard and soft casing formats, plus DEHP-free media. - Sangtech says the filter achieves leukoreduction to fewer than 0.3×10⁶ residual white cells per unit. - Sangtech says red cell recovery is above 92%. - The company says the filter meets ISO 10993-5 cytotoxicity grade 0, with no solvent residuals to extract. - Sangtech says the filter removes 98% to 100% of platelets without activation. - The company says CellNet PR received a 2026 Edison Award Silver in Energy & Climate Resiliency. - Sangtech also says CellNet PR received a 2026 R&D 100 Award for water-free and solvent-free surface functionalization of fibers, developed with the Taiwan Textile Research Institute. - Sangtech says the process is covered by U.S. Patent No. 11,224,686 B2. - The company says the product is not a finished medical device, and that finished-device performance and regulatory clearance are the responsibility of the integrating manufacturer. - Sangtech says the full announcement and company information are available at the company’s website.
Between the lines: - The pitch is less about a single filter and more about a manufacturing platform that could change how medical membranes are processed. - Sangtech is trying to turn sustainability into a purchasing criterion for transfusion systems, not just a corporate reporting metric. - The DEHP-free angle also aligns with a broader regulatory shift in medical materials away from phthalates. - The company is making a strong exclusivity claim, but it also invites evidence to the contrary, which suggests the market position may be subject to challenge.
What's next: - Sangtech will likely continue supplying media and semi-finished filters to device makers that integrate the product into finished blood filtration systems. - The next commercial step depends on manufacturers obtaining their own regulatory clearance for finished devices. - Broader adoption will hinge on whether blood services and device makers value the solvent-free, zero-wastewater manufacturing process enough to switch suppliers. - Sangtech said it welcomes documented evidence if another commercial whole-blood leukoreduction filter is manufactured the same way.
The bottom line: - CellNet PR is being marketed as both a performance filter and a cleaner manufacturing platform, with sustainability now part of the product value proposition.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Healthy Living Europe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.